Association of soluble TREM2 with Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis

被引:2
|
作者
Wang, Ruiqi [1 ]
Zhan, Yijun [1 ]
Zhu, Wenyan [1 ]
Yang, Qianwen [1 ]
Pei, Jian [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Acupuncture, Shanghai, Peoples R China
来源
FRONTIERS IN AGING NEUROSCIENCE | 2024年 / 16卷
关键词
soluble TREM2; Alzheimer's disease; mild cognitive impairment; neuroinflammation; meta-analysis; BIOMARKERS; EXPRESSION; MICROGLIA; INSIGHTS; VARIANT;
D O I
10.3389/fnagi.2024.1407980
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) is a potential neuroinflammatory biomarker linked to the pathogenesis of Alzheimer's disease (AD) and mild cognitive impairment (MCI). Previous studies have produced inconsistent results regarding sTREM2 levels in various clinical stages of AD. This study aims to establish the correlation between sTREM2 levels and AD progression through a meta-analysis of sTREM2 levels in cerebrospinal fluid (CSF) and blood. Methods Comprehensive searches were conducted in PubMed, Embase, Web of Science, and the Cochrane Library to identify observational studies reporting CSF and blood sTREM2 levels in AD patients, MCI patients, and healthy controls. A random effects meta-analysis was used to calculate the standardized mean difference (SMD) and 95% confidence intervals (CIs). Results Thirty-six observational studies involving 3,016 AD patients, 3,533 MCI patients, and 4,510 healthy controls were included. CSF sTREM2 levels were significantly higher in both the AD [SMD = 0.28, 95% CI (0.15, 0.41)] and MCI groups [SMD = 0.30, 95% CI (0.13, 0.47)] compared to the healthy control group. However, no significant differences in expression were detected between the AD and MCI groups [SMD = 0.09, 95% CI (-0.09, 0.26)]. Furthermore, increased plasma sTREM2 levels were associated with a higher risk of AD [SMD = 0.42, 95% CI (0.01, 0.83)]. Conclusion CSF sTREM2 levels are positively associated with an increased risk of AD and MCI. Plasma sTREM2 levels were notably higher in the AD group than in the control group and may serve as a promising biomarker for diagnosing AD. However, sTREM2 levels are not effective for distinguishing between different disease stages of AD. Further investigations are needed to explore the longitudinal changes in sTREM2 levels, particularly plasma sTREM2 levels, during AD progression. Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024514593
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer's Disease
    Liu, Changan
    Yu, Jun
    FRONTIERS IN AGING NEUROSCIENCE, 2019, 11
  • [42] Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis
    Chen, Leian
    Niu, Xiaoqian
    Wang, Yuye
    Lv, Shuang
    Zhou, Xiao
    Yang, Ziyuan
    Peng, Dantao
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [43] Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis
    Qu, Yi
    Ma, Ya-Hui
    Huang, Yu-Yuan
    Ou, Ya-Nan
    Shen, Xue-Ning
    Chen, Shi-Dong
    Dong, Qiang
    Tan, Lan
    Yu, Jin-Tai
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2021, 128 : 479 - 486
  • [44] Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease
    Heslegrave, Amanda
    Heywood, Wendy
    Paterson, Ross
    Magdalinou, Nadia
    Svensson, Johan
    Johansson, Per
    Ohrfelt, Annika
    Blennow, Kaj
    Hardy, John
    Schott, Jonathan
    Mills, Kevin
    Zetterberg, Henrik
    MOLECULAR NEURODEGENERATION, 2016, 11
  • [45] Neurofilament Light Chain as a Potential Biomarker in Plasma for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and a Meta-Analysis
    Fan, Zhenyi
    Liu, Xiaoxia
    Liu, Jie
    Chen, Caijing
    Zhou, Min
    JOURNAL OF INTEGRATIVE NEUROSCIENCE, 2023, 22 (04)
  • [46] TREM2 in Alzheimer's disease
    Jiang, Teng
    Yu, Jin-Tai
    Zhu, Xi-Chen
    Tan, Lan
    MOLECULAR NEUROBIOLOGY, 2013, 48 (01) : 180 - 185
  • [47] Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer's Disease: Systematic Review and Meta-Analysis
    Zabala-Findlay, Alex
    Penny, Lewis K.
    Lofthouse, Richard A.
    Porter, Andrew J.
    Palliyil, Soumya
    Harrington, Charles R.
    Wischik, Claude M.
    Arastoo, Mohammad
    CELLS, 2023, 12 (08)
  • [48] A Systematic Review and Meta-Analysis of On-Road Simulator and Cognitive Driving Assessment in Alzheimer's Disease and Mild Cognitive Impairment
    Hird, Megan A.
    Egeto, Peter
    Fischer, Corinne E.
    Naglie, Gary
    Schweizer, Tom A.
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 53 (02) : 713 - 729
  • [49] Does Soluble TREM2 Protect Against Alzheimer's Disease?
    Brown, Guy C.
    St George-Hyslop, Peter
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 13
  • [50] Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
    Kristi Henjum
    Ina S. Almdahl
    Vibeke Årskog
    Lennart Minthon
    Oskar Hansson
    Tormod Fladby
    Lars N. G. Nilsson
    Alzheimer's Research & Therapy, 8